47141-42-4

Basic information

• Product Name: LEVOBUNOLOL
• Synonyms: LEVOBUNOLOL;[(-)-5-[3,(t-Butylamino)-2-hydroxy-propoxy]-3,4-di,HCl;5-[(2S)-3-[(1,1-Dimethylethyl)amino]-2-hydroxypropoxy]-3,4-dihydro-1(2H)-naphthalenone;5-[(S)-3-[(1,1-Dimethylethyl)amino]-2-hydroxypropoxy]-3,4-dihydronaphthalen-1(2H)-one;5-[3-(tert-Butylamino)-2β-hydroxypropyloxy]-3,4-dihydronaphthalen-1(2H)-one;(S)-5-[3-[(1,1-DiMethylethyl)aMino]-2-hydroxypropoxy]- 3,4-dihydro-1(2H)-naphthalenone;l-Bunolol;W 6421A
• CAS NO: 47141-42-4
• Molecular Formula: C17H25NO3
• Molecular Weight: 291.39
• Product Categories: Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 47141-42-4.mol
• Article Data: 9

Chemical Properties

• Melting Point: 209-211°C
• Appearance: white to pink powder
• Storage Temp.: -20?C Freezer, Under Inert Atmosphere
• CAS DataBase Reference: LEVOBUNOLOL(CAS DataBase Reference)
• NIST Chemistry Reference: LEVOBUNOLOL(47141-42-4)
• EPA Substance Registry System: LEVOBUNOLOL(47141-42-4)

Safety Data

• Hazardous Substances Data: 47141-42-4(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

Originator

Betagan,Allergan,India

Uses

Different sources of media describe the Uses of 47141-42-4 differently. You can refer to the following data:
1. Levobunolol hydrochloride is an antiglaucoma agent in ophthalmie solutions.
2. As a non-selective adrenoceptor antagonist, Levobunolol is used as an anticonvulsant.

Definition

ChEBI: A cyclic ketone that is 3,4-dihydronaphthalen-1-one substituted at position 5 by a 3-(tert-butylamino)-2-hydroxypropoxy group (the S-enantiomer). A non-selective beta-adrenergic antagonist used (as its hydrochlo ide salt) for treatment of glaucoma.

Brand name

Akbeta(Akorn); Betagan(Allergan).

Therapeutic Function

Beta-adrenergic blocker

InChI:InChI=1/C17H25NO3/c1-17(2,3)18-10-12(19)11-21-16-9-5-6-13-14(16)7-4-8-15(13)20/h5-6,9,12,18-19H,4,7-8,10-11H2,1-3H3/t12-/m0/s1

Upstream product

• 28315-93-7 5-Hydroxy-1-tetralone 
• 75-64-9 tert-butylamine 
• 106-89-8 epichlorohydrin 

Relevant articles and documents

FLUORESCENCE BASED DETECTION OF SUBSTANCES

A method for the fluorescent detection of a substance, the method comprising providing particles comprising a metal or a metal oxide core, wherein one or more optionally fluorescently tagged antibodies or human specific peptide nucleic acid (PNA) oligomers for binding to a substance is/are bound, directly or indirectly, to the surface of the metal or metal oxide; contacting a substrate, which may or may not have the substance on its surface, with the particles for a time sufficient to allow the antibody/PNA oligomer to bind with the substance; removing those particles which have not bound to the substrate; if the antibodies or PNA oligomers are not fluorescently tagged, contacting the substrate with one or more fluorophores that selectively bind with the antibody and/or substance, then optionally washing the substrate to remove unbound fluorophores; and illuminating the substrate with appropriate radiation to show the fluorophores on the substrate.

ANTIHYPERTENSIVE THERAPY

A new use of darusentan is provided in preparation of a pharmaceutical composition for lowering blood pressure in a patient exhibiting resistance to a baseline antihypertensive therapy with one or more drugs. The composition comprises darusentan in an amount providing a therapeutically effective daily dose; wherein (a) the composition is orally deliverable and/or (b) the daily dose of darusentan is effective to provide a reduction of at least about 3 mmHg in one or more blood pressure parameters selected from trough sitting systolic, trough sitting diastolic, 24-hour ambulatory systolic, 24-hour ambulatory diastolic, maximum diurnal systolic and maximum diurnal diastolic blood pressures. Further provided is a new use of darusentan in preparation of a pharmaceutical composition for lowering blood pressure in a patient exhibiting resistance to a baseline antihypertensive therapy, wherein the composition is administered adjunctively with at least one diuretic and at least one antihypertensive drug selected from ACE inhibitors, angiotensin II receptor blockers, beta-adrenergic receptor blockers and calcium channel blockers.

Reversible gelation emulsion compositions and methods of use

Reversibly gelling aqueous and oil emulsions are disclosed which can be modified to incorporate oil soluble pharmaceutical compounds for delivery to physiological systems in a soluble form and which undergo significant changes in viscosity in response to substantially simultaneous changes in both temperature and pH. The compositions are formed of relatively low concentrations of a stable combination of at least one pH-sensitive reversibly gelling polymer, at least one temperature-sensitive reversibly gelling polymer and at least one organic oil. The compositions can be formulated to exhibit a sol-gel transition over a wide range of conditions and viscosities and may be modified to incorporate a pharmaceutical compound for utilization as droppable or injectable drug delivery systems which will gel following administration to a physiological system for the sustained delivery of such pharmaceutical compounds.